Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:VVUS

VIVUS (VVUS) Stock Price, News & Analysis

VIVUS logo

About VIVUS Stock (NASDAQ:VVUS)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.26
$0.47
52-Week Range
N/A
Volume
2.03 million shs
Average Volume
1.44 million shs
Market Capitalization
$7.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive VVUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VIVUS and its competitors with MarketBeat's FREE daily newsletter.

VVUS Stock News Headlines

Presidential Bombshell: $150T Resource to Be Released as soon as this Summer?
Something extraordinary is happening in Washington. For the first time in over a century, a sitting President could release a national treasure that's been tied up in red tape, for generations. I'm talking about a $150 trillion American asset that's scattered across all 50 states. While the mainstream media focuses on political theater, this story is quietly developing behind closed doors.
VIVUS Launches QSYMIA® in the United Arab Emirates
VIVUS Shares Significant Regulatory Update on QSYMIA®
VIVUS Announces Label Update for QSYMIA®
See More Headlines

VVUS Stock Analysis - Frequently Asked Questions

VIVUS, Inc. (NASDAQ:VVUS) posted its earnings results on Wednesday, May, 6th. The biopharmaceutical company reported ($0.49) EPS for the quarter, beating analysts' consensus estimates of ($0.80) by $0.31. The biopharmaceutical company had revenue of $19.63 million for the quarter.

VIVUS's stock reverse split on the morning of Tuesday, September 11th 2018.The 1-10 reverse split was announced on Monday, September 10th 2018. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 10th 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that VIVUS investors own include Fulcrum Therapeutics (FULC), Sangamo Therapeutics (SGMO), Anavex Life Sciences (AVXL), Advanced Micro Devices (AMD), Novavax (NVAX), CymaBay Therapeutics (CBAY) and Amarin (AMRN).

Company Calendar

Last Earnings
5/06/2020
Today
7/12/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:VVUS
CIK
881524
Fax
N/A
Employees
57
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($2.96)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$31.50 million
Net Margins
-39.28%
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-12.18%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.43
Quick Ratio
0.28

Sales & Book Value

Annual Sales
$69.76 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($6.50) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
17,867,000
Free Float
N/A
Market Cap
$7.33 million
Optionable
Optionable
Beta
-0.84
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:VVUS) was last updated on 7/13/2025 by MarketBeat.com Staff
From Our Partners